Short communication

31P MRS ANALYSIS OF THE PHOSPHOLIPID COMPOSITION OF THE PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) AND BONE MARROW MONONUCLEAR CELLS (BMMC) OF PATIENTS WITH ACUTE LEUKEMIA (AL)

MAŁGORZATA KULISZKIEWICZ-JANUS1, 2*, MARIUSZ ADAM TUZ1, MAREK KIELBIŃSKI1, BOŻENA JAŻWIEC1, JOANNA NIEDOBA1 and STANISŁAW BACZYŃSKI3

1Department of Haematology and Transplantology, Wrocław Medical University, Wrocław, Poland, 2Academic Centre for the Biotechnology of Lipid Aggregates, Wrocław, Poland, 3Faculty of Chemistry, University of Wrocław, Wrocław, Poland

Abstract: The aim of this study was to evaluate the phospholipid concentration in acute leukemia (AL) blast cells from peripheral blood (PBMC) and bone marrow (BMMC). In vitro 31P Nuclear Magnetic Resonance Spectroscopy (31P MRS) was used. The integral intensities of the resonant peaks and the phospholipid concentrations in PBMC and BMMC were analyzed. Differences in the phospholipid concentrations in cells from myeloblastic or lymphoblastic lines were also evaluated. This investigation was carried out on phospholipid extracts from PBMC and BMMC from 15 healthy volunteers and 77 patients with AL (samples taken at the moment of diagnosis). A significant decrease in sphingomyelin (SM) and phosphatidyserine (PS) was observed in the PBMC of patients with AL relative to the results for the healthy volunteers. For ALL, we...
found a significant decrease in the concentration of phosphatidylcholine plasmalogen (CPLAS), SM, PI+PE (phosphatidylinositol + phosphatidylethanolamine) and PS in comparison with the results for healthy volunteers and patients with AML. Experiments with BMMC cells revealed a significant decrease in the concentration of CPLAS, SM, PI+PE, and PS in ALL relative to AML. Additionally, a significant decrease in phosphatidylcholine (PC) concentration was observed in ALL compared to AML. If the phospholipid extracts were taken simultaneously from the same patient, there were no significant differences in the integral intensities and phospholipid concentrations between PBMC and BMMC.

Key words: Acute leukemia, 31P MRS, Phospholipids

INTRODUCTION

Establishing the concentration of phospholipids in malignant cells and their role in apoptosis is the aim of a great deal of research. To continue our previous studies on the application of 31P MRS to the analysis of phospholipid changes in the sera [1-6], plasma [7], and peripheral blood and bone marrow mononuclear cells [8-10] from patients with blood cancer diseases, we decided to evaluate phospholipid concentrations in acute leukemia cells from the peripheral blood (PBMC) and bone marrow (BMMC). We also evaluated differences in the phospholipid concentrations in blast cells from myeloblastic and lymphoblastic lines. The in vitro 31P MRS method was applied. On the basis of the received 31P spectra of the phospholipid extracts from those cell types, the integral intensities of the resonant peaks for phospholipids and methylenediphosphonic acid (MDPA) were analyzed, and thus, the phospholipid concentrations could be calculated.

MATERIALS AND METHODS

This investigation was carried out on phospholipid extracts from the PBMC of 15 healthy volunteers and 55 patients with acute leukemia (18 with ALL and 37 with AML) and from the BMMC of 44 patients with acute leukemia (11 with ALL and 29 with AML). Experiments were also carried out on extract couples obtained simultaneously from the peripheral blood and bone marrow (PBMC/BMMC ALP+B) of 13 patients with acute leukemia (Tab. 1).

The phospholipid extracts were obtained using the modified Folch method. 31P NMR spectra were received on an AMX 300 Bruker (7.05 T) spectrometer. All the applied methods in this investigation were described in previous publications [7, 8, 10].
Tab. 1. Investigated groups.

| Group                | All | Females | Males | Age (Median) |
|----------------------|-----|---------|-------|--------------|
| Zₚ                   |     |         |       | 22-55 (24)  |
| ALₚ (= ALLₚ+AMLₚ)    | 55  | 21      | 34    | 17-76 (49)  |
|                      |     |         |       |              |
|                      |     |         |       |              |
| ALLₚ                 | 18  | 5       | 13    | 17-62 (27)  |
| AMLₚ                 | 37  | 16      | 21    | 30-76 (58)  |
| M₂ₚ                  | 12  | 6       | 6     | 30-76 (60)  |
| M₄ₚ                  | 15  | 6       | 9     | 36-74 (61)  |

PBMC

| ALₐ (= ALLₐ+AMLₐ)    | 40  | 18      | 22    | 22-79 (56)  |
|                      |     |         |       |              |
|                      |     |         |       |              |
| ALLₐ                 | 11  | 4       | 7     | 23-76 (29)  |
| AMLₐ                 | 29  | 14      | 15    | 22-79 (57)  |

BMMC

| ALₐ+ALₐ               | 13  | 5       | 8     | 22-55 (25)  |

Zₚ – healthy volunteers, ALₚ – acute leukemia patients from whom PBMC were obtained, ALLₚ – ALL patients from whom PBMC were obtained, AMLₚ – AML patients from whom PBMC were obtained, M₂ₚ – AML M2 patients from whom PBMC were obtained, ALₐ – acute leukemia patients from whom BMMC were obtained, ALLₐ – ALL patients from whom BMMC were obtained, AMLₐ – AML patients from whom BMMC were obtained, ALₐ+ALₐ – acute leukemia patients from whom PBMC and BMMC were obtained simultaneously.

RESULTS AND DISCUSSION

The ³¹P NMR spectra of the phospholipid extracts from the PBMC of the healthy volunteers (Zₚ) consisted of 7 resonant peaks due to phospholipids – PC, CPLAS, SM, PI+PE, PS, and CL (cardiolipin) – and one other due to MDPA, the external reference substance. The resonant peak due to CL was only observed in 6 of 15 individuals. The ³¹P NMR spectrum of the phospholipid extracts from the PBMC of the healthy volunteers is shown in Fig. 1.

The phospholipid concentrations in the investigated extracts are based on the integral intensities of the resonant peaks due to phospholipids and MDPA (Tab. 2). A significant decrease in the integral intensities of the resonant peaks due to SM and PS was observed in the spectra of the phospholipid extracts from the PBMC of the ALₚ group patients (Fig. 1). Additionally, the peak due to CPLAS was not observed in 25.4% of patients, that due to SM in 25.4%, that due to PI+PE in 3.6%, that due to PS in 32.7%, and that due to CL in 89.1%. The concentrations of SM and PS were significantly decreased in comparison with the Zₚ group. The concentration decrease for PS was 66.7%, and for SM was 50.0%.

The spectra of the phospholipid extracts from PBMC were compared between patients with ALL (ALLₚ group) and with AML (AMLₚ group). A significant decrease in the resonant peaks due to CPLAS, SM, PI+PE and PS was observed in the spectra for the ALLₚ group patients in comparison with those for the AMLₚ group patients (Fig. 2). Similar differences were observed for phospholipid concentrations in the groups mentioned above (Tab. 2).
Fig. 1. The $^{31}$P NMR spectra of phospholipid extracts from PBMC: PL in reference to MDPA (A), for healthy volunteers (B) and for patients with AL (C).

Additionally, the peak due to CPLAS was not observed in 44.4% of the ALLP patients, that due to SM in 33.3%, that due to PI+PE in 5.6%, that due to PS in 50.0%, and that due to CL in 94.4%. The concentrations of phospholipids mentioned above for the ALLP group were significantly decreased relative to those for the ZP group.

The peak due to CPLAS was not observed in 16.2% of patients with AMLP, that due to SM in 21.6%, that due to PI+PE in 2.7%, that due to PS in 24.3%, and that due to CL in 84.5%. The concentrations of SM and PS in the extracts from PBMC were significantly diminished in the AMLP group relative to those for the ZP group (Tab. 2). There were no significant differences in the phospholipid concentrations in the PBMC extracts between M$_{2P}$ and M$_{4P}$ according to the FAB (French-American-British Classification) of Acute Leukaemia (Tab. 2). The $^{31}$P NMR spectra of phospholipid extracts from the BMMC of AL patients (ALB group) at the moment of diagnosis consisted of 7 resonant peaks due to the phospholipids PC, CPLAS, SM, PI, PE, PS, and CL, and another due to MDPA (as with the spectra of PBMC) (Fig. 3). There was no peak due to CPLAS in 30.0% of patients, none due to SM in 25.0%, none due to PI+PE in 7.5%, none due to PS in 40.0%, and none due to CL in 75.0%. The phospholipid concentrations in the BMMC extracts of the ALB, ALLB, AMLB groups are shown in Tab. 2.
Tab. 2. The phospholipid concentrations in the investigated groups.

| Phospholipids C (mmol/l) | PC     | CPLAS   | SM     | PI+PE  | PS     | CL     |
|--------------------------|--------|---------|--------|--------|--------|--------|
| Zp, n = 15               | 0.41 ± 0.03 | 0.04 ± 0.01 | 0.15 ± 0.01 | 0.29 ± 0.04 | 0.09 ± 0.01 | 0.03 ± 0.01 |
| ALp, n = 55              | 0.37 ± 0.03 | 0.04 ± 0.01 | 0.07 ± 0.01 | 0.23 ± 0.02 | 0.03 ± 0.01 | 0.01 ± 0.00 |
| ALLp, n = 18             | 0.31 ± 0.04 | 0.01 ± 0.01 | 0.05 ± 0.01 | 0.14 ± 0.02 | 0.01 ± 0.00 | 0.00 ± 0.00 |
| AMLp, n = 37             | 0.40 ± 0.03 | 0.05 ± 0.01 | 0.09 ± 0.01 | 0.27 ± 0.03 | 0.04 ± 0.01 | 0.01 ± 0.01 |
| M2, n = 12               | 0.44 ± 0.07 | 0.05 ± 0.01 | 0.07 ± 0.02 | 0.27 ± 0.06 | 0.04 ± 0.02 | 0.00 ± 0.00 |
| M4, n = 15               | 0.42 ± 0.03 | 0.05 ± 0.01 | 0.11 ± 0.01 | 0.29 ± 0.03 | 0.04 ± 0.01 | 0.01 ± 0.01 |
| ALn, n = 40              | 0.34 ± 0.03 | 0.04 ± 0.01 | 0.08 ± 0.01 | 0.23 ± 0.02 | 0.00 ± 0.01 | 0.01 ± 0.00 |
| ALLn, n = 11             | 0.23 ± 0.05 | 0.01 ± 0.01 | 0.03 ± 0.02 | 0.14 ± 0.04 | 0.01 ± 0.01 | 0.00 ± 0.00 |
| AMLn, n = 29             | 0.39 ± 0.03 | 0.05 ± 0.01 | 0.11 ± 0.01 | 0.26 ± 0.02 | 0.04 ± 0.01 | 0.02 ± 0.01 |
| PBMC/BMMMC, ALp, n = 13  | 0.37 ± 0.05 | 0.05 ± 0.01 | 0.08 ± 0.02 | 0.26 ± 0.04 | 0.04 ± 0.01 | 0.02 ± 0.01 |
| ALn                      | 0.33 ± 0.04 | 0.03 ± 0.01 | 0.07 ± 0.02 | 0.21 ± 0.03 | 0.03 ± 0.01 | 0.01 ± 0.01 |

p-value

Zp – healthy volunteers, ALp – acute leukemia patients from whom PBMC were obtained, ALLp – ALL patients from whom PBMC were obtained, AMLp – AML patients from whom PBMC were obtained, M2p – AML M2 patients from whom PBMC were obtained, ALn – acute leukemia patients from whom BMMC were obtained, ALLn – ALL patients from whom BMMC were obtained, AMLn – AML patients from whom BMMC were obtained, ALp+B – acute leukemia patients from whom PBMC and BMMC were obtained simultaneously.

A significant decrease in the integral intensities of the resonant peaks due to PC, CPLAS, SM, PI+PE, and PS and its concentrations was observed in the spectra for patients of the ALLn group relative to those for the AMLn group (as with the spectra for the PBMC groups) (Fig. 4). Additionally, the resonant peak due to CPLAS was not observed in 81.8% of patients of the ALLn group, that due to SM in 63.6%, that due to PI+PE in 18.2%, and that due to PS in 90.9%. There was no peak due to CL for any patient. The resonant peak due to CPLAS was not observed in 10.3% of AMLn patients, that due to SM in 10.3%, that due to PI+PE in 3.4%, that due to PS in 20.7%, and that due to CL in 65.5%.

The 31P NMR spectra of phospholipid extracts from PBMC and BMMC were compared. These spectra originated from the same patients, from whom samples were collected simultaneously (PBMC/BMMMC: ALp+ALn). There were no significant differences between these groups in terms of the integral intensities of resonant peaks or phospholipid concentrations (Tab. 2).
Fig. 2. The $^{31}$P NMR spectra of phospholipid extracts from the PBMC of patients in the active stage of acute leukemia: lymphoblastic (A), myeloblastic M2 (B), and myeloblastic M4 (C) type.

Fig. 3. The $^{31}$P NMR spectra of phospholipid extracts from BMMC: PL in reference to MDPA (A), patients with AL (B).

Many sphingolipids, such as ceramide, sphingosine, sphingosine-1-phosphate (SP1), ceramide-1-phosphate and lyso-sphingomyelin, play regulatory roles in cell growth, death, adhesion, migration, inflammation, angiogenesis and intracellular signalling. On the basis of the data from the spectra of PBMC received from patients with AL (AML_P and ALL_P), it was claimed that the
integral intensities of resonant peaks due to SM and PS and the concentrations of these phospholipids are significantly diminished in comparison with those for healthy volunteers. Similar differences were observed by Merchant et al., who investigated malignant changes in the tissues of the esophagus and colon [11, 12].

![Image of 31P NMR spectra](image)

Fig. 4. The $^{31}$P NMR spectra of phospholipid extracts from the BMMC of ALL patients (A) and AML patients (B).

Eicosanoids, phosphoinositides, sphingolipids and fatty acids are signalling lipids which play an important role in cellular processes like cell proliferation, apoptosis, metabolism and migration. Cytokines, growth factors and nutrients initiate signal transduction events and modify the activity of lipid-modifying enzymes: phospholipases, prostaglandin synthase 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase. Thus, the complex signalling network is initiated by multiple nodes of interaction, with cross-regulation where imbalance leads to disease. One such important lipid is sphingomyelin. This phospholipid is located in the outer leaflet of membranes. SM is present in a small amount in the inner leaflet. Sphingomyelinase causes SM hydrolysis into ceramide and phosphorylcholine. The role of ceramide in the initiation phase of apoptosis is probably to be the second mediator, while in the effector phase, it takes part in apoptotic cell generation and membrane blebbing/vesiculation [13, 14]. On the basis of the aforementioned studies, it can be presumed that the deficiency of SM in the cell membranes of acute leukemic cells can cause a decrease in the ceramide concentration and influence the decrease in apoptotic cell death efficiency. It could be an additional factor for malignant cell maintenance and its accumulation in organisms.

In our investigation, the decrease in SM concentration was accompanied by a decrease in PS concentration. The disturbed amount of PS in the cell may cause disturbances of apoptotic processes. PS, which is located in the inner leaflet of cell membranes, gives a signal by externalization into the outer leaflet for phagocytes to recognize and remove apoptotic cells [15-20]. This decrease in PS level was observed also by Merchant et al. in malignant esophageal tissues [11].
We focused on the significant difference in the integral intensities and phospholipid concentrations of SM and PS as well as CPLAS and PI+PE between the ALL-P and AML-P groups. In the ALL-P group, these values were diminished in comparison with both the AML-P group and the healthy volunteers. In the AML-P group, only the levels of SM and PS were significantly decreased in comparison to those for the healthy volunteers. Similar observations were found in the phospholipid extracts from BMMC. For the patients with ALL-B, a significant decrease in PC, CPLAS, SM, PI+PE and PS was observed compared to patients with AML-B.

Studies concerning PE, especially lysophosphatidic acid acyltransferase-beta (LPAAT-beta), which takes part in lysophosphatidic acid acylation, could prove the existence of differences between the activity of this enzyme in ALL and AML. Upon the action of phospholipase, PE breaks up into ethanolamine and phosphatidic acid (PA). PA is also generated by lysophosphatidic acid acylation, which is catalyzed by lysophosphatidic acid acyltransferases (LPAATs). One of these acyltransferases is lysophosphatidic acid acyltransferase-beta (LPAAT-beta) [21]. The overexpression of this enzyme was proven in malignant changed ovaries [22, 23]. The increased overexpression of LPAAT-beta was not observed in the PBMC and BMMC of patients with AL and cell lines (AML193, Molt4, U937, CEM and K562) in comparison with healthy volunteers. It was proven that the level of this enzyme depends on the AL type. Increased activity was observed in ALL compared to AML. It was claimed that the cell sensitivity for the action of the LPAAT-beta inhibitor (CT-32228) is more increased in AML than ALL [24]. The increased demand for PA in ALL in comparison to AML and the possibility of receiving this phospholipid from PE can be the cause of the decrease in PI+PE observed by us in PBMC and BMMC from patients with ALL. Similar explanations can concern PC, which on the action of phospholipase D breaks up into choline and PA [25].

Data on the behavior of CPLAS in the PBMC and BMMC of acute leukemia was discussed by the authors of an earlier paper [9]. Differences in the lipid content in cell membranes were also observed between lympho- and myeloblastic cells from peripheral blood from children with acute leukemia [26]. We found differences in the structure of lymphoblastic membranes in comparison to leukocytes from healthy volunteers and in comparison to myeloblasts.

There are other methods which reveal differences in the apoptotic mechanisms of lympho- and myeloblastic cells. This was shown by Wu Lin et al. [27], who confirmed the increased activity of caspase-3 in PBMC from patients with AML in comparison with ALL. It can indicate an increased susceptibility of PBMC to apoptosis in AML in comparison to ALL [28]. These results concur with the data obtained by Invernizzi et al. [29], who observed the largest decrease of the amount of apoptotic cells in patients with ALL (1.0 ± 0.5) compared to patients with AML (8.6 ± 2.3), with MDS (16.7 ± 3.4) and healthy volunteers (10.8 ± 1.4).
The results of the abovementioned studies and our own observations indicate differences in the processes in the blast cells of lymphoblastic and myeloblastic lines. This can give opportunities to find new treatments for acute leukemia.

REFERENCES

1. Kuliszkwicz-Janus, M. and Baczyński, S. Chemotherapy-associated changes in $^{31}$P MRS spectra of sera from patients with multiple myeloma. NMR Biomed. 8 (1995) 127-132.
2. Kuliszkwicz-Janus, M. and Baczyński, S. Application of $^{31}$P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn. Reson. Med. 35 (1996) 449-456.
3. Kuliszkwicz-Janus, M. and Baczyński, S. Treatment induces changes in $^{31}$P MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia. Biochim. Biophys. Acta 1360 (1997) 71-83.
4. Kuliszkwicz-Janus, M., Janus, W. and Baczyński, S. Application of $^{31}$P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res. 16 (1996) 1587-1594.
5. Kuliszkwicz-Janus, M., Janus, W., Baczyński, S. and Jurczyk, A. Bone marrow transplantation In the course of hematological malignancies- fellow up to study in blood serum by $^{31}$P NMR. Med. Sci. Monit. 10 (2004) 485-492.
6. Kuliszkwicz-Janus, M., Tuz, M.A. and Baczyński, S. Application of $^{31}$P NMR to the analysis of phospholipids changes in plasma of patients with acute leukemia. Biochim. Biophys. Acta 1737 (2005) 11-15.
7. Kuliszkwicz-Janus, M. and Baczyński, S. Phospholipids' sera and mononuclear cells in acute leukemia, malignant lymphoma and multiple myeloma - evaluation by $^{31}$P MRS in vitro. NATO Science Series. II: Mathematics, Physics and Chemistry 76 (2002) 347-354.
8. Tuz, M.A., Kuliszkwicz-Janus, M. and Baczyński, S. Application of $^{31}$P NMR magnetic resonance spectroscopy to observation of phospholipids concentration changes in blood serum, plasma, peripheral blood mononuclear cells and bone marrow mononuclear cell from patients with hematological cancers - a methodological review. Polish J. Chem. 80 (2006) 1009-1019.
9. Kuliszkwicz-Janus, M., Tuz, M.A., Kielbiński, M., Baczyński, S., Jaźwiec, B. and Śladowska, H. Platelet-activating factor changes In phospholipid extracts from plasma, peripheral blood mononuclear cells and bone marrow mononuclear cell of patients with acute leukemia - A $^{31}$P NMR in vitro study. Cell. Mol. Biol. Lett. 13 (2008) 58-66.
10. Kuliszkwicz-Janus, M., Tuz, M.A., Baczyński, S., Prajs, I. and Jaźwiec, B. $^{31}$P NMR analysis of the phospholipid composition of normal human
peripheral blond mononuclear cells (PBMC). Cell. Mol. Biol. Lett. 10 (2005) 373-382.

11. Merchant, T.E, de Graaf, P.W., Minsky, B.D., Obertop, H. and Glonek, T. Esophageal cancer phospholipid characterization by $^{31}$P NMR. NMR Biomed. 6 (1993) 187-193.

12. Merchant, T.E., Minsky, B.D., Lauwers, G.Y., Diamantis, P.M., Haida, T. and Glonek, T. Esophageal cancer phospholipids correlated with histopathologic findings: A $^{31}$P NMR study. NMR Biomed. 12 (1999) 184-188.

13. van Blitterswijk, W.J., van der Luit, A.H., Veldman, R.J., Verheij, M. and Borst, J. Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem. J. 369 (2003) 199-211.

14. Tepper, A.D., Ruurs, P., Wiedmer, T., Sims, P.J., Borst, J. and van Blitterswijk, W.J. Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipids scrambling and alters cell-surface morphology. J. Cell Biol. 150 (2000) 155-164.

15. Bevers, EM., Comfurius, P., Dekkers, D.W. and Zwaal, R.F. Lipid translocation across the plasma membrane of mammalian cells. Biochim. Biophys. Acta 1439 (1999) 317-330.

16. Verhoven, B., Schlegel, R.A. and Williamson, P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J. Exp. Med. 182 (1995) 1597-1601.

17. Martin, S.J., Reutelingsperger, C.P., McGahon, A.J., Rader, J.A., van Schie, R.C., LaFace, D.M. and Green, D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182 (1995) 1545-1556.

18. Fadok, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Bratton, D.L. and Henson, P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148 (1992) 2207-2216.

19. Kagan, V.E., Fabisiak, J.P., Shvedova, A.A., Tyurina, Y.Y., Tyurin, V.A., Schor, N.F. and Kawai, K. Oxidative signaling pathway for externalization of plasma membrane phosphatidylserine during apoptosis. FEBS Lett. 477 (2000) 1-7.

20. McConkey, D.J., Zhitovsky, B. and Orrenius, S. Apoptosis – molecular mechanisms and biomedical implications. Mol. Aspects Med. 17 (1996) 1-110.

21. Eberhardt, C., Gray, P.W. and Tjoelker, L.W. Human lysoosphatidic acid acyltransferase. CDNA cloning, expression, and localization to chromosome 9q34.3. J. Biol. Chem. 272 (1997) 20299-20305.

22. Niesporek, S., Denkert, C., Weichert, W., Kobel, M., Noske, A., Sehouli, J., Singer, J.W., Dietel, M. and Hauptmann, S. Expression of lysoosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis. Br. J. Cancer 92 (2005) 1729-1736.
23. Springett, G.M., Bonham, L., Hummer, A., Linkov, I., Misra, D., Ma, C., Pezzoni, G., Di Giovine, S., Singer, J., Kawasaki, H., Spriggs, D., Soslow, R. and Dupont, J. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res. 65 (2005) 9415-9425.

24. Douvas, M.G., Hogan, K.N., Ji, Y., Hollenback, D., Bonham, L., Singer, J.W. and Mitchell, B.S. Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk. Res. 30 (2006) 1027-1036.

25. Ruiz-Cabello, J. and Cohen, J.S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 5 (1992) 226-233.

26. Gerhard, A., Häfer, R. and Zintl, F. Fatty acid composition of lymphocyte membrane phospholipids in children with acute leukaemia. Cancer Lett. 173 (2001) 139–144.

27. Lin, W.C., Manshouri, T., Jilani, I., Neuberg, D., Patel, K., Kantarjian, H., Andreeff, M., Estrov, Z., Beran, M., Keating, M., Estey, E. and Albitar, M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk. Res. 26 (2002) 551-559.

28. Shuler, D. and Szende, B. Apoptosis in acute leukaemia. Leuk. Res. 28 (2004) 661-666.

29. Invernizzi, R., Pecchi, A., Bellotti, L. and Ascarì, E. Expression of p53, Bcl-2 and Ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk. Lymphoma 42 (2001) 481-489.